Clinical trial
A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)
NCT05204368 is registered in ClinicalTrials.gov with Evopoint Biosciences Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)
- Lead sponsor
- Evopoint Biosciences Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 30, 2023
- Completion date
- December 31, 2025
- Enrollment
- 780 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
complicated urinary tract infection including acute pyelonephritis